HighPoint Advisor Group LLC Reduces Position in Kenvue Inc. (NYSE:KVUE)

HighPoint Advisor Group LLC trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,608 shares of the company’s stock after selling 569 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Kenvue were worth $1,816,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Franklin Resources Inc. lifted its position in Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after buying an additional 16,269,721 shares in the last quarter. B. Metzler seel. Sohn & Co. AG increased its stake in shares of Kenvue by 17.6% in the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 131,477 shares of the company’s stock worth $2,807,000 after acquiring an additional 19,693 shares during the last quarter. Skba Capital Management LLC raised its holdings in shares of Kenvue by 6.4% during the 4th quarter. Skba Capital Management LLC now owns 601,330 shares of the company’s stock worth $12,838,000 after acquiring an additional 36,070 shares during the period. O Shaughnessy Asset Management LLC boosted its position in shares of Kenvue by 28.4% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 59,771 shares of the company’s stock valued at $1,276,000 after acquiring an additional 13,203 shares during the last quarter. Finally, Schroder Investment Management Group grew its holdings in shares of Kenvue by 0.6% in the fourth quarter. Schroder Investment Management Group now owns 160,305 shares of the company’s stock valued at $3,395,000 after purchasing an additional 950 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 1.1 %

Shares of KVUE opened at $23.97 on Tuesday. The company’s 50-day simple moving average is $22.38 and its 200-day simple moving average is $22.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market capitalization of $45.80 billion, a PE ratio of 45.22, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.42%. Kenvue’s payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of analyst reports. Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. UBS Group reduced their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.